近5日机构合计调研302家公司，肇民科技、中微公司、华测检测等被多家机构扎堆调研。 证券时报·数据宝统计，近5个交易日（5月27日至6月3日）两市约302家公司被机构调研，调研机构类型 显示，证券公司共对272家公司进行调研，即90.07%的上市公司调研活动有证券公司参与；基金公司调 研232家，位列其后；阳光私募机构调研119家，排名第三。 机构调研榜单中，共有69家公司获20家以上机构扎堆调研。肇民科技最受关注，参与调研的机构达到 281家；中微公司被212家机构调研，榜单中排名第二；华测检测、拓荆科技等分别被187家、179家机构 调研。 机构调研次数来看，三友联众机构调研最为密集，共获机构4次调研。能辉科技、周大生等机构调研也 较为密集，均被机构调研3次。 数据宝统计，20家以上机构扎堆调研股中，近5日资金净流入的有24只，中科金财近5日净流入资金4.04 亿元，主力资金净流入最多；净流入资金较多的还有海大集团、北特科技等，净流入资金分别为2.46亿 元、1.27亿元。 市场表现上，机构扎堆调研股中，近5日上涨的有27只，涨幅居前的有华纳药厂、科兴制药、益方生物 等，涨幅为64.66%、53.29%、 ...

Group 1: Investor Relations Activities - The company conducted a series of investor relations activities from March 4 to May 30, 2025, including online meetings and on-site research, involving a total of 10 to 40 participants per event [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25]. Group 2: Business Development in High-Tech Fields - The company has strategically invested in high-tech and emerging technology sectors, focusing on AI, humanoid robots, and low-altitude economy, enhancing its service offerings in these areas [6][7]. - In the automotive sector, particularly in new energy vehicles, the company has established deep collaborations with numerous manufacturers, ensuring safety and reliability in vehicle testing [9][10]. Group 3: Digital Financial Technology - The company has developed a three-dimensional testing system for digital financial technology products, achieving national-level testing qualifications for client-side and embedded software [8]. - Recent acquisitions have strengthened the company's position in the cybersecurity assessment market, expanding its service capabilities across multiple regions [8]. Group 4: Semiconductor and Chip Industry - The company remains optimistic about the long-term potential of the semiconductor industry, actively pursuing transformation and investment in key areas such as FA and MA [11]. - The company has optimized its management team and is focusing on enhancing operational capabilities to adapt to market changes [11]. Group 5: Pharmaceutical and Medical Sector - The pharmaceutical sector has shown signs of recovery after a period of adjustment, with a focus on high-value areas and stable client relationships [12][13]. - The company has completed the construction of comprehensive testing capabilities for medical devices, ensuring steady growth in revenue and profit [12][13]. Group 6: Future Revenue and Profit Growth - The company has maintained a strategic focus on long-term growth despite economic challenges, implementing a "123 strategy" to enhance operational efficiency and market positioning [14][22]. - The company plans to optimize resource allocation to create a balanced portfolio of cash flow, high-growth, and future reserve businesses [14]. Group 7: Mergers and Acquisitions Strategy - The company is actively pursuing strategic mergers and acquisitions to enhance its international competitiveness, focusing on sectors such as consumer goods and transportation [15][18]. - Recent acquisitions include the purchase of ALS Group's subsidiary in China, aimed at expanding capabilities in geochemical testing [19][20]. Group 8: Shareholder Returns and Dividends - The company has implemented a cash dividend policy, distributing RMB 1 per 10 shares to shareholders, with a historical payout ratio of 64.01% over the past three years [21]. - The board is considering increasing mid-term cash dividends to enhance shareholder returns [21]. Group 9: Strategic Resilience Amid Uncertainty - The company is committed to maintaining strategic stability in the face of external uncertainties, focusing on lean management and operational excellence [22][23]. - Plans include the integration of AI technologies to improve efficiency and service quality across various business segments [23][24].

Investment Rating - The report maintains an "Overweight" rating for the mechanical equipment industry [1]. Core Insights - The mechanical equipment industry is experiencing an upward trend, particularly in construction machinery, with a notable recovery in excavator sales and a shift in demand towards non-excavator machinery [2][3]. - The humanoid robot sector is advancing, with Tesla's Optimus showcasing enhanced learning capabilities, which could accelerate commercialization [2]. - The forklift market is seeing mixed performance, with domestic sales declining slightly while exports are growing, driven by increased lithium battery penetration [3]. Summary by Sections Recommended Stocks - The report suggests a focus on companies such as Northern Huachuang, Sany Heavy Industry, and others across various segments including humanoid robots, engineering machinery, and forklifts [1][12]. Engineering Machinery - Excavator sales have shown a recovery, with April 2025 figures indicating a year-on-year increase of 18% [2]. - The demand for road machinery is on the rise, with significant growth in sales of rollers and pavers [2]. - The report highlights the importance of overseas markets, particularly in Southeast Asia and Africa, for future growth in engineering machinery exports [15][17]. Forklift Market - In April 2025, forklift sales reached 130,000 units, with exports increasing by 18% while domestic sales fell by 1% [3]. - The report notes that domestic manufacturing sentiment is weak, impacting local sales, but the export market remains robust due to improved overseas distribution channels [3]. Humanoid Robots - The report emphasizes the importance of generalization capabilities in humanoid robots, with Tesla's Optimus demonstrating significant advancements in skill acquisition [2]. - The application of humanoid robots in logistics and other sectors is becoming increasingly essential, indicating a growing market demand [2]. General Automation - The industrial automation sector is showing signs of recovery, with specific recommendations for companies like Estun and others in the FA automation space [28]. - The report notes that the injection molding machine market is maturing domestically, with significant potential for overseas expansion [29]. Detection Services - The detection services sector is expected to benefit from government stimulus and a recovery in domestic demand, with leading companies like Huace Detection showing resilience [34][36].

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 1 per 10 shares and no bonus shares, approved by the shareholders' meeting held on May 19, 2025 [1][2][3]. Summary by Sections Shareholders Meeting Approval - The profit distribution plan was approved during the 2024 annual shareholders' meeting, with a cash dividend of RMB 1 per 10 shares (including tax) and no bonus shares [1][2]. Profit Distribution Plan - The total share capital for the distribution is 1,672,828,214 shares after excluding 10,000,000 repurchased shares. The total cash dividend amount is calculated to be RMB 167,282,821.40 [4][8]. Dividend Payment Details - The cash dividends will be directly credited to shareholders' accounts on May 28, 2025, through their respective securities companies [7]. - Different tax rates apply for various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors [4][8]. Record and Ex-Dividend Dates - The record date for the dividend distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [4][5]. Calculation of Dividend and Reference Price - The reference price for the ex-dividend will be adjusted based on the cash dividend distributed per share, calculated as RMB 0.0994057 per share [8].

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 1 per 10 shares and no bonus shares, approved by the shareholders' meeting held on May 19, 2025 [1][2]. Summary by Sections 1. Profit Distribution Plan - The profit distribution plan involves a cash dividend of RMB 1 per 10 shares (including tax) for all shareholders, with no bonus shares distributed [1][2]. - The total amount for distribution will not exceed the distributable profits as per the financial statements, and adjustments will be made if the total share capital changes before implementation [1][2]. 2. Key Dates - The record date for the profit distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [2]. 3. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies on the ex-dividend date [3]. 4. Calculation of Dividend - The actual cash dividend amount is calculated based on the total share capital minus repurchased shares, resulting in a cash dividend of approximately RMB 0.994057 per 10 shares [4]. - The reference price for the ex-dividend will be adjusted based on the cash dividend amount and the total share capital on the record date [4]. 5. Consultation Information - The company provides contact details for inquiries regarding the profit distribution plan, including a contact person and phone numbers [3].

证券代码：300012 证券简称：华测检测 公告编号：2025-028 华测检测认证集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华测检测认证集团股份有限公司（以下简称"公司"）2024 年年度权益分 派方案已获 2025 年 5 月 19 日召开的 2024 年度股东大会审议通过，现将权益分 派事宜公告如下： 一、股东大会审议通过权益分派方案情况 1、公司 2024 年度股东大会审议通过分配方案的具体内容：以公司实施利润 分配方案时股权登记日可参与利润分配的总股本为基数，向全体股东每 10 股派 发现金股利人民币 1 元（含税），送红股 0 股，以资本公积金向全体股东每 10 股转增 0 股。本次利润分配预案公布后至实施前，如公司参与分红总股本由于股 份回购、股权激励、员工持股计划等原因而发生变化时，按照分配比例不变的原 则，以未来实施本次分配预案时股权登记日参与分红的公司总股本为基数进行利 润分配，分红金额总额相应调整，公司预计分配总额不会超过财务报表上可供分 配利润。 现金（含税；扣税后，通过深股通持 ...

Investment Rating - The report suggests a focus on leading companies with strong management and brand recognition in the testing service industry, particularly recommending companies like Huace Testing, Sutest, and Guangdian Measurement [6][13][44]. Core Viewpoints - The testing service sector is under pressure, with a focus on lean management and the expansion of emerging industries. The overall revenue for the sector in 2024 is projected to be 46.8 billion RMB, a decrease of 4% year-on-year, primarily due to macroeconomic slowdowns and ongoing policy impacts in the pharmaceutical and special industries [4][18]. - The sector's growth is closely tied to macroeconomic performance, with expectations for recovery in demand due to government debt relief and stimulus policies [5][75]. - The industry is experiencing a trend towards consolidation, with resources expected to concentrate among leading firms that possess brand, capital, and management advantages [5][70]. Summary by Sections Revenue Performance - In 2024, the testing service sector achieved a revenue of 46.8 billion RMB, down 4% year-on-year. Excluding companies with high medical testing ratios, the sector's revenue was 25.8 billion RMB, showing a 4% increase year-on-year [4][18]. - The first quarter of 2024 saw a revenue of 9 billion RMB, a 9% decline year-on-year, but excluding high medical testing companies, the revenue growth rate improved to 2% [4][18]. Profitability - The sector's net profit for 2024 is expected to be 1.8 billion RMB, a significant decline of 56% year-on-year, attributed to decreased revenue, rigid laboratory costs, and reduced government subsidies [25]. - Leading companies like Huace Testing and Guangdian Measurement showed resilience, with net profit growth rates of 1% and 77% respectively in 2024 [25][18]. Market Trends - The global testing service market is projected to reach approximately 2.3 trillion RMB in 2024, with a compound annual growth rate (CAGR) of about 6% from 2021 to 2024. China's testing service industry has historically grown at about twice the GDP growth rate [5][58]. - The industry is characterized by a high degree of fragmentation, with small and weak players facing challenges in capital and management, leading to a trend towards consolidation [69][70]. Emerging Opportunities - New sectors such as semiconductors and low-altitude economy are developing rapidly, creating new demands for testing services that require significant capital and technical capabilities [6][70]. - The report emphasizes the importance of government policies in supporting the testing service industry, particularly through debt relief measures that could enhance demand recovery [75][86].

证券代码：300012 证券简称：华测检测 公告编号：2025-027 华测检测认证集团股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决议案的情况； 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 1、会议召开时间： 5、主持人：董事长万峰先生。 6、公司董事、监事、高级管理人员出席了本次会议，见证律师列席了本次 会议。 7、本次股东大会的召开符合《公司法》《公司章程》等法律、法规及规范 性文件的规定。 （1）现场会议召开时间：2025 年 5 月 19 日（星期一）下午 14:30。 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的时间为 2025 年 5 月 19 日上午 9:15-9:25，9:30-11:30，下午 13:00-15：00；通过深圳证券 交易所互联网投票系统投票的具体时间为 2025 年 5 月 19 日 9:15-15:00 期间的 任意时间。 2、召开地点：深圳市宝安区新安街道留仙三路 4 号华测检测大楼一楼会议 ...

广东华商律师事务所 关于华测检测认证集团股份有限公司 2024 年度股东大会的 法律意见书 2025 年 5 月 中国深圳福田区深南大道 4011 号香港中旅大厦 第 21A-3 层、第 22A、23A、24A、25A、26A 层 广东华商律师事务所 关于华测检测认证集团股份有限公司 2024 年度股东大会的 法律意见书 致：华测检测认证集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）及中国证券监督管理委员会《上市公司 股东大会规则》（以下简称"《股东大会规则》"）等法律、法规及规范性文件的 规定，广东华商律师事务所（以下简称"本所"）接受华测检测认证集团股份有限 公司（以下简称"公司"）的委托，指派刘丽萍律师、张梅林律师出席了公司2024 年度股东大会（以下简称"本次股东大会"），就本次股东大会的有关问题，依法 出具本法律意见书。 本法律意见书仅就本次股东大会的召集和召开程序、出席本次股东大会人员的 资格、召集人资格、会议表决程序是否符合法律、法规及《公司章程》的规定以及 表决结果是否合法有效发表意见，并不对本次股东大会所审议的议 ...

Investment Rating - The report suggests a focus on leading companies with strong management and brand recognition in the testing service industry, particularly recommending companies like Huace Testing, Sutest, and Guangdian Measurement [6][13][86]. Core Insights - The overall performance of the testing service industry is under pressure, with a focus on lean management and the expansion into emerging industries [4][5]. - The testing service sector is closely correlated with macroeconomic growth, and it is expected to benefit from government debt relief and domestic demand stimulus policies [5][74]. - The industry is experiencing a trend towards consolidation, with resources likely to concentrate in leading companies that possess brand, capital, and management advantages [5][6]. Summary by Sections Revenue Performance - In 2024, the testing service sector achieved revenue of 46.8 billion RMB, a year-on-year decline of 4%. Excluding companies with high medical testing ratios, the revenue was 25.8 billion RMB, showing a growth of 4% [4][19]. - The first quarter of 2024 saw a revenue of 9 billion RMB, down 9% year-on-year, but excluding high medical testing companies, the revenue growth improved to 2% [4][19]. Profitability - The sector's net profit attributable to shareholders in 2024 was 1.8 billion RMB, down 56% year-on-year, primarily due to declining revenue and increased costs [26]. - Excluding high medical testing companies, the net profit decline was 20%, indicating a narrowing drop [26]. Market Dynamics - The global testing service market is projected to reach approximately 2.3 trillion RMB in 2024, with a CAGR of about 6% from 2021 to 2024 [5][57]. - The Chinese testing service market reached around 467 billion RMB in 2023, with a CAGR of 13% from 2014 to 2023 [57]. Industry Characteristics - The testing service industry is characterized by heavy asset requirements and localized operations, with a significant presence of small and weak institutions [68][69]. - The report highlights a trend towards consolidation in the industry, driven by increasing regulatory scrutiny and the need for higher capital and technical capabilities in emerging sectors [69][73]. Future Outlook - The report anticipates a recovery in demand for the testing service industry due to recent macroeconomic policy adjustments and government debt relief measures [74][86]. - Companies with significant government client bases, such as Puni Testing, Guangdian Measurement, and Huace Testing, are expected to benefit from these developments [86].